Latest News & Insight: October 9, 2014

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.